ResultsIQ › Latest results › Anuh Pharma Limited
Anuh Pharma Limited Q2 FY27 results deck summary
NSE: ANUHPHR · BSE: 506260
Results deck of 6 Nov 2026, summarised by AI from the filing.
Anuh Pharma's H1 FY27 PAT rose 42.25% to ₹22.64 cr on broadly flat revenue of ₹379.05 cr as margin improved to 9.74%.
Key takeaways
- H1 FY27 PAT PAT rose to ₹22.64 cr (H1 FY26: ₹15.91 cr, +42.25% YoY) on revenue of ₹379.05 cr, broadly flat.
Anuh Pharma Limited Q2 FY27 results
As filed: Revenue ₹185 cr (0% year on year), EBITDA ₹16.9 cr (+41% year on year), PAT ₹11.2 cr (+40% year on year), EBITDA margin 9.1% (+269 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹194 cr (+4% year on year), EBITDA ₹16.3 cr (+48% year on year), PAT ₹11.4 cr (+43% year on year), EBITDA margin 8.4% (+249 bps). Score 70 of 100, Above trend. EBITDA margin rose 249 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 4% from last quarter. Share price after the results: +2.2% in 28 days (Nifty 500: −1.9%).
- Q4 FY26: Revenue ₹202 cr (+2% year on year), EBITDA ₹19.9 cr (+5% year on year), PAT ₹11.7 cr (−3% year on year), EBITDA margin 9.8% (+24 bps). Score 35 of 100, Below trend. EBITDA margin rose 24 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 13% from last quarter. Share price after the results: −4.4% in 30 days (Nifty 500: +2.5%).
- Q3 FY26: Revenue ₹197 cr (+23% year on year), EBITDA ₹16.8 cr (+20% year on year), PAT ₹13.5 cr (+35% year on year), EBITDA margin 8.5% (−23 bps). Score 68 of 100, Above trend. EBITDA margin fell 23 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −2.1% in 28 days (Nifty 500: −4.1%).
- Q2 FY26: Revenue ₹186 cr, EBITDA ₹12.0 cr, PAT ₹8.0 cr, EBITDA margin 6.5%. Not scored. No result for the same quarter last year. Share price after the results: −4.3% in 28 days (Nifty 500: +1.3%).
- Q1 FY26: Revenue ₹186 cr, EBITDA ₹11.0 cr, PAT ₹8.0 cr, EBITDA margin 5.9%. Not scored. No result for the same quarter last year. Share price after the results: −7.0% in 28 days (Nifty 500: +1.7%).
- Q4 FY25: Revenue ₹198 cr, EBITDA ₹19.0 cr, PAT ₹12.0 cr, EBITDA margin 9.6%. Not scored. No result for the same quarter last year. Share price after the results: −0.4% in 28 days (Nifty 500: +1.1%).
- Q3 FY25: Revenue ₹160 cr, EBITDA ₹14.0 cr, PAT ₹10.0 cr, EBITDA margin 8.8%. Not scored. No result for the same quarter last year.
Past price moves after results do not indicate future moves. Not a recommendation.
Anuh Pharma Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Results deck (6 Nov 2026)
- Q1 FY27: Results deck (19 Aug 2026)
- Q4 FY26: Results deck (28 May 2026)
- Q3 FY26: Results deck (13 Feb 2026)
- Q2 FY26: Results deck (17 Nov 2025)
- Q1 FY26: Results deck (22 Aug 2025)
- Q4 FY25: Results deck (29 May 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.